Cargando…

Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection

The use of bacterial spores in probiotics over viable loads of bacteria has many advantages, including the durability of spores, which allows spore-based probiotics to effectively traverse the various biochemical barriers present in the gastrointestinal tract. However, the majority of spore-based pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosnar, Luke M., Shindler, Anya E., Wood, Jennifer, Patch, Craig, Franks, Ashley E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267654/
https://www.ncbi.nlm.nih.gov/pubmed/37323944
http://dx.doi.org/10.1099/acmi.0.000419
_version_ 1785058971096186880
author Bosnar, Luke M.
Shindler, Anya E.
Wood, Jennifer
Patch, Craig
Franks, Ashley E.
author_facet Bosnar, Luke M.
Shindler, Anya E.
Wood, Jennifer
Patch, Craig
Franks, Ashley E.
author_sort Bosnar, Luke M.
collection PubMed
description The use of bacterial spores in probiotics over viable loads of bacteria has many advantages, including the durability of spores, which allows spore-based probiotics to effectively traverse the various biochemical barriers present in the gastrointestinal tract. However, the majority of spore-based probiotics developed currently aim to treat adults, and there is a litany of differences between the adult and infant intestinal systems, including the immaturity and low microbial species diversity observed within the intestines of infants. These differences are only further exacerbated in premature infants with necrotizing enterocolitis (NEC) and indicates that what may be appropriate for an adult or even a healthy full-term infant may not be suited for an unhealthy premature infant. Complications from using spore-based probiotics for premature infants with NEC may involve the spores remaining dormant and adhering to the intestinal epithelia, the out-competing of commensal bacteria by spores, and most importantly the innate antibiotic resistance of spores. Also, the ability of Bacillus subtilis to produce spores under duress may result in less B. subtilis perishing within the intestines and releasing membrane branched-chain fatty acids. The isolate B. subtilis BG01-4(TM) is a proprietary strain developed by Vernx Biotechnology through accumulating mutations within the BG01-4(TM) genome in a serial batch culture. Strain BG01-4(TM) was provided as a non-spore-forming B. subtilis , but a positive sporulation status for BG01-4(TM) was confirmed through in vitro testing and suggested that selection for the sporulation defective genes could occur within an environment that would select against sporulation. The durability of key sporulation genes was ratified in this study, as the ability of BG01-4(TM) to produce spores was not eliminated by the attempts to select against sporulation genes in BG01-4(TM) by the epigenetic factors of high glucose and low pH. However, a variation in the genes in isolate BG01-4-8 involved in the regulation of sporulation is believed to have occurred during the mutation selection from the parent strain BG01-4(TM). An alteration in selected sporulation regulation genes is expected to have occurred from BG01-4(TM) to BG01-4-8, with BG01-4-8 producing spores within 24 h, ~48 h quicker than BG01-4(TM).
format Online
Article
Text
id pubmed-10267654
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Microbiology Society
record_format MEDLINE/PubMed
spelling pubmed-102676542023-06-15 Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection Bosnar, Luke M. Shindler, Anya E. Wood, Jennifer Patch, Craig Franks, Ashley E. Access Microbiol Research Articles The use of bacterial spores in probiotics over viable loads of bacteria has many advantages, including the durability of spores, which allows spore-based probiotics to effectively traverse the various biochemical barriers present in the gastrointestinal tract. However, the majority of spore-based probiotics developed currently aim to treat adults, and there is a litany of differences between the adult and infant intestinal systems, including the immaturity and low microbial species diversity observed within the intestines of infants. These differences are only further exacerbated in premature infants with necrotizing enterocolitis (NEC) and indicates that what may be appropriate for an adult or even a healthy full-term infant may not be suited for an unhealthy premature infant. Complications from using spore-based probiotics for premature infants with NEC may involve the spores remaining dormant and adhering to the intestinal epithelia, the out-competing of commensal bacteria by spores, and most importantly the innate antibiotic resistance of spores. Also, the ability of Bacillus subtilis to produce spores under duress may result in less B. subtilis perishing within the intestines and releasing membrane branched-chain fatty acids. The isolate B. subtilis BG01-4(TM) is a proprietary strain developed by Vernx Biotechnology through accumulating mutations within the BG01-4(TM) genome in a serial batch culture. Strain BG01-4(TM) was provided as a non-spore-forming B. subtilis , but a positive sporulation status for BG01-4(TM) was confirmed through in vitro testing and suggested that selection for the sporulation defective genes could occur within an environment that would select against sporulation. The durability of key sporulation genes was ratified in this study, as the ability of BG01-4(TM) to produce spores was not eliminated by the attempts to select against sporulation genes in BG01-4(TM) by the epigenetic factors of high glucose and low pH. However, a variation in the genes in isolate BG01-4-8 involved in the regulation of sporulation is believed to have occurred during the mutation selection from the parent strain BG01-4(TM). An alteration in selected sporulation regulation genes is expected to have occurred from BG01-4(TM) to BG01-4-8, with BG01-4-8 producing spores within 24 h, ~48 h quicker than BG01-4(TM). Microbiology Society 2023-05-26 /pmc/articles/PMC10267654/ /pubmed/37323944 http://dx.doi.org/10.1099/acmi.0.000419 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
spellingShingle Research Articles
Bosnar, Luke M.
Shindler, Anya E.
Wood, Jennifer
Patch, Craig
Franks, Ashley E.
Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title_full Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title_fullStr Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title_full_unstemmed Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title_short Attempts to limit sporulation in the probiotic strain Bacillus subtilis BG01-4(TM) through mutation accumulation and selection
title_sort attempts to limit sporulation in the probiotic strain bacillus subtilis bg01-4(tm) through mutation accumulation and selection
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267654/
https://www.ncbi.nlm.nih.gov/pubmed/37323944
http://dx.doi.org/10.1099/acmi.0.000419
work_keys_str_mv AT bosnarlukem attemptstolimitsporulationintheprobioticstrainbacillussubtilisbg014tmthroughmutationaccumulationandselection
AT shindleranyae attemptstolimitsporulationintheprobioticstrainbacillussubtilisbg014tmthroughmutationaccumulationandselection
AT woodjennifer attemptstolimitsporulationintheprobioticstrainbacillussubtilisbg014tmthroughmutationaccumulationandselection
AT patchcraig attemptstolimitsporulationintheprobioticstrainbacillussubtilisbg014tmthroughmutationaccumulationandselection
AT franksashleye attemptstolimitsporulationintheprobioticstrainbacillussubtilisbg014tmthroughmutationaccumulationandselection